Healthcare industry

One year after its seed financing, SpinDiag GmbH closes a second financing round of EUR 3 million (USD 3.4 million) as planned. The financing will enable SpinDiag to complete the product development of its first product for screening for antibiotic-resistant bacteria and to start clinical trials. This will pave the way for regulatory approval in the EU.

Article - 23/03/2015

Crowdfunding: a new source of money for the healthcare sector?

Crowdfunding has become a popular widely-talked-about financing tool that opens up new ways of acquiring money for projects that might not otherwise receive backing. The financing model is based on the simple idea of raising many small amounts of capital to finance a large project. In early 2015 a company called Riboxx secured the capital it needed through a campaign on the Seedmatch crowdfunding platform. The German company aescuvest GmbH…

Press release - 14/10/2009

mtm laboratories Extends Series C Financing Round by EUR 7 Million Bringing Total to EUR 39 Million (USD 57 Million)

mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, announced on 14th October the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company’s last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in…

A consortium of leading life-science venture capital funds invests € 18.5 million in the German medical diagnostics company Curetis AG. This financing will enable Curetis to complete development of its innovative diagnostic products through to market entry.

The Baden-Württemberg Ministry of Finance and Economics presented the results of two studies that evaluated the innovative strength of Baden-Württemberg in comparison to other regions around the world. The studies were carried out by the University of Hohenheim and the independent research institute BAK Basel Economics AG BAK Basel on behalf of the Baden-Württemberg Ministry of Finance and Economics and they were financed by the Baden-Württemberg…

Press release - 26/11/2014

Curetis Closes EUR 14.5 Million Extension of Series B Financing

Curetis AG wins new investors QIAGEN and LSP-HEF, committing EUR 7 million. Hence Curetis is well financed into 2017. Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013.

Press release - 21/09/2010

immatics raises 54 million euros to advance its late stage clinical therapeutic cancer vaccine portfolio

immatics biotechnologies GmbH a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer announced today that it has raised 53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics existing pipeline of advanced therapeutic cancer vaccine candidates.

VC-facts has published the Life Sciences Venture Capital Yearbook for the first time 2007. It shows that the total volume of financing in the life sciences amounts to 438.65 million euros.

Press release - 02/05/2013

Curetis raises EUR 12.5 million in Series B round led by new investor HBM Partners

On the 22nd April 2013 the Curetis AG in Holzgerlingen announced the closing of a Series B financing round totaling EUR 12.5 million. The financing was led by HBM Partners. Dr. Alexander Asam of HBM will join Curetis’ supervisory board. Curetis will use the proceeds for the next phase of commercial and operational growth.

At the end of the year Alessandro Banchi 62 Chairman of the Board of Directors at Boehringer Ingelheim GmbH and head of Marketing and Sales is to be succeeded by the Vice-Chairman of the Board of Managing Directors Dr. Andreas Barner 55.

The University of Ulm will receive an endowed professorship for research into neurodegenerative diseases. The Charcot Foundation will fund the professorship with 500000 over the next five years.

Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.

Press release - 15/10/2013

Biotech financing in Baden-Württemberg: immatics raises 34 million Euros

The immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a 34 million Euros Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the fundraising, immatics will receive…

Article - 09/06/2009

We would gladly finance more biotechs

For four years, the High-Tech Gründerfonds (high-tech company establishment fund) has been supporting technology-oriented company founders. The project, which is backed by the Federal German government and major businesses, has 272 million euros of largely federal funds at its disposal, and its objective is the accelerated marketability of ideas. We spoke with Marco Winzer, representative and Investment Director at High-Tech Gründerfonds,…

Press release - 14/08/2010

Data management and new simulation methods for the virtual liver

Researchers at the Heidelberg Institute for Theoretical Studies HITS are part of the national Virtual Liver Network initiated and financed by the German Federal Ministry of Education and Research BMBF.

Press release - 19/07/2012

Subitec GmbH raises 4.5 Mio Euros in second round financing

Subitec GmbH, a manufacturer of fully automated algae photobioreactors, hascloseda second round of financing. The CleantechFonds of eCAPITAL entrepreneurial Partners AG, Fraunhofer Venture, High-Tech Gründerfonds (HTGF) and KfW Bankengruppe’s ERP-Startfonds participated in the capital increase. Subitec funds to the amount of 4.5 Mio Euros will accrue in this round of financing. The raised capital is to be used mainly for launching bioreactors on…

Press release - 09/12/2015

New financing conditions from High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is raising its seed investment to €600k and lowering interest rates by 4%. This is in response to changing requirements in the start-up and venture capital scene, as well as current interest rate trends. The package of measures will be effective from January 1, 2016.

The 14th Biotech Finance Forum offered selected biotechnology and medical technology companies from all over Europe the opportunity of an exclusive meeting with internationally operative investors from the venture capital VC scene.

Press release - 23/04/2010

Ernst & Young: "German Biotechnology Report 2010"

During the global crisis in 2009, the revenues, number of companies and the number of employees in the German biotechnology industry remained unchanged from the previous year. However, considerable progress was made in terms of product development and market admissions. As in the previous year, 2009 saw a strong slump in terms of equity financing. Investments in research and developments fell. Collaborations and strategic alliances acted as…

With a € 1.5 Mio Second Closing, Curetis has now increased its Series A financing round to € 20 Mio. This additional financing will enable Curetis to complete the development of its innovative diagnostic products through to market entry. Quality Certification for its diagnostic product development represents an additional milestone in Curetis' commercial strategy. At the same time, Curetis has added internationally recognized expertise in…

Press release - 22/10/2009

SYGNIS secures up to € 10 Million through a 3 year Standby Equity Distribution Agreement (SEDA) with Yorkville

SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard), a clinical stage biotech company developing innovative CNS treatments, today announced that it has entered into a 3 year standby equity distribution agreement (SEDA) with YA Global Master SPV LTD (YA Global) a fund managed by Yorkville Advisors, LLC located in New Jersey USA.

Novaliq GmbH, a drug delivery company focusing on difficult to dissolve substances for ophthalmic and dermatological applications, announced the conclusion of a round of financing talks resulting in €3.9 million.

Press release - 08/10/2012

Affimed raises € 15.5 million in a Series D financing round

Affimed Therapeutics AG the therapeutic TandAb antibody company announced the successful closing of a Series D financing round of 15.5 million on 8 October 2012. The proceeds from this transaction will be used to fund the clinical development of Affimeds therapeutic pipeline that consists of two TandAb products AFM11 and AFM13. Both candidates have unique properties as shown in preclinical studies.

Eggenstein-Leopoldshafen – 14 December 2016: amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, today announced the closing of a Series B financing round amounting to a total of EUR 6 million.

The German Federal Ministry of Education and Research BMBF is to finance a new Bernstein Focus on Neurotechnology at the Universities of Freiburg and Tübingen with funds totalling ten million euros. The new initiative is part of the Computational Neuroscience funding programme.